Cargando…

Functional Characterization of Transforming Growth Factor-β Signaling in Dasatinib Resistance and Pre-BCR(+) Acute Lymphoblastic Leukemia

SIMPLE SUMMARY: We focus on the characterization of the transforming growth factor-β (TGFβ) signaling pathway in B acute lymphoblastic leukemia (ALL) and in resistance to the multi-kinase inhibitor dasatinib in order to provide a better understanding of the molecular and functional mechanisms underl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mostufi-Zadeh-Haghighi, Gila, Veratti, Pia, Zodel, Kyra, Greve, Gabriele, Waterhouse, Miguel, Zeiser, Robert, Cleary, Michael L., Lübbert, Michael, Duque-Afonso, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486903/ https://www.ncbi.nlm.nih.gov/pubmed/37686604 http://dx.doi.org/10.3390/cancers15174328

Ejemplares similares

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
por: Fei, Fei, et al.
Publicado: (2010)

BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy
por: Yamada, Chika, et al.
Publicado: (2021)

Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia
por: Han, Hye-ji, et al.
Publicado: (2022)

Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians
por: Dieterle, Martin Philipp, et al.
Publicado: (2023)

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
por: Xiao, Xinhua, et al.
Publicado: (2020)

Dasatinib‐induced hypoglycemia in a patient with acute lymphoblastic leukemia
por: Lundholm, Michelle D., et al.
Publicado: (2020)

Novel FIP1L1::KIT fusion in a myeloid neoplasm with eosinophilia, T-lymphoblastic transformation, and dasatinib response
por: Alsouqi, Aseel, et al.
Publicado: (2023)

Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia
por: Grüninger, Patricia K., et al.
Publicado: (2022)

Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia
por: Sarno, Jolanda, et al.
Publicado: (2023)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat
por: Blagitko-Dorfs, Nadja, et al.
Publicado: (2013)

Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2020)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2021)

AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
por: Rejeski, Kai, et al.
Publicado: (2021)

Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1–transformed acute lymphoblastic leukemia cells
por: Feldhahn, Niklas, et al.
Publicado: (2007)

Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis
por: Rettig, Andrés R., et al.
Publicado: (2021)

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants
por: Ye, Wu, et al.
Publicado: (2022)

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
por: Hughes, T P, et al.
Publicado: (2015)

Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Sugiura, Isamu, et al.
Publicado: (2022)

Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation
por: Waterhouse, Miguel, et al.
Publicado: (2022)

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2020)

Myeloid/lymphoid neoplasm with eosinophilia and BCR/FGFR1 rearrangement with transformation to cortical T-lymphoblastic lymphoma and erythroid precursors: a case report
por: Isaza, Alejandro Pineda, et al.
Publicado: (2023)

A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib
por: Ali, Elrazi Awadelkarim Hamid, et al.
Publicado: (2021)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia
por: Boer, Judith M., et al.
Publicado: (2016)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007)

Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia
por: Feldhahn, Niklas, et al.
Publicado: (2012)

BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy
por: Cario, Gunnar, et al.
Publicado: (2020)

Role of Vitamins A and D in BCR-ABL Arf(−/−) Acute Lymphoblastic Leukemia
por: Annu, Kavya, et al.
Publicado: (2020)

Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia
por: Scherr, Michaela, et al.
Publicado: (2018)

Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Abdelrasoul, Hend, et al.
Publicado: (2020)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
por: Stomper, Julia, et al.
Publicado: (2021)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

Transforming Growth Factor β Signaling Overcomes Dasatinib Resistance in Lung Cancer
por: Gordian, Edna, et al.
Publicado: (2014)

T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association
por: Faizan, Mahwish, et al.
Publicado: (2021)

A Case of Dasatinib-Induced Nephrotic Syndrome in a Child with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
por: Lim, Young Tae, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cldgv7kdla9ggogr87tvpf8cff